Drug Profile

NAV 003 - Navrogen

Alternative Names: NAV-003 - Navrogen

Latest Information Update: 19 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Navrogen
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

19 Apr 2023 Preclinical trials in Solid tumours in USA (Parenteral) (Navrogen pipeline, April 2023)
14 Apr 2023 Pharmacodynamics data from a preclinical studies presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR 2023)
03 Jun 2021 Early research in Solid tumours in USA (Unspecified) (Navrogen pipeline, June 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com